Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients

Creative Commons License

Hafez G., Malyszko J., Golenia A., Klimkowicz-Mrowiec A., Ferreira A. C., ARICI M., ...Daha Fazla

CLINICAL KIDNEY JOURNAL, sa.12, ss.2378-2392, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1093/ckj/sfad239
  • Dergi Adı: CLINICAL KIDNEY JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.2378-2392
  • Hacettepe Üniversitesi Adresli: Evet

Özet

There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. Graphical Abstract